CytoMed Net Tangible Assets from 2010 to 2026
| GDTC Stock | 1.08 0.23 27.06% |
Net Tangible Assets | First Reported 2010-12-31 | Previous Quarter 511.4 K | Current Value 485.8 K | Quarterly Volatility 719.4 K |
Check CytoMed Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CytoMed Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 136.6 K, Other Operating Expenses of 3.2 M or Research Development of 1 M, as well as many indicators such as Price To Sales Ratio of 358, Dividend Yield of 0.0 or PTB Ratio of 6.53. CytoMed financial statements analysis is a perfect complement when working with CytoMed Therapeutics Valuation or Volatility modules.
CytoMed | Net Tangible Assets | Build AI portfolio with CytoMed Stock |
Analyzing CytoMed Therapeutics's Net Tangible Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Tangible Assets has evolved provides context for assessing CytoMed Therapeutics's current valuation and future prospects.
Latest CytoMed Therapeutics' Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of CytoMed Therapeutics Limited over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. CytoMed Therapeutics' Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CytoMed Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
CytoMed Net Tangible Assets Regression Statistics
| Arithmetic Mean | 1,441,905 | |
| Geometric Mean | 1,216,554 | |
| Coefficient Of Variation | 49.89 | |
| Mean Deviation | 649,301 | |
| Median | 1,882,000 | |
| Standard Deviation | 719,368 | |
| Sample Variance | 517.5B | |
| Range | 2.1M | |
| R-Value | (0.71) | |
| Mean Square Error | 272.7B | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | (101,324) | |
| Total Sum of Squares | 8.3T |
CytoMed Net Tangible Assets History
About CytoMed Therapeutics Financial Statements
CytoMed Therapeutics stakeholders use historical fundamental indicators, such as CytoMed Therapeutics' Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although CytoMed Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in CytoMed Therapeutics' assets and liabilities are reflected in the revenues and expenses on CytoMed Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in CytoMed Therapeutics Limited. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 511.4 K | 485.8 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether CytoMed Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CytoMed Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytomed Therapeutics Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytomed Therapeutics Limited Stock:Check out the analysis of CytoMed Therapeutics Correlation against competitors. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Will Biotechnology sector continue expanding? Could CytoMed diversify its offerings? Factors like these will boost the valuation of CytoMed Therapeutics. Market participants price CytoMed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every CytoMed Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.25) | Revenue Per Share | Quarterly Revenue Growth 1.01 | Return On Assets | Return On Equity |
The market value of CytoMed Therapeutics is measured differently than its book value, which is the value of CytoMed that is recorded on the company's balance sheet. Investors also form their own opinion of CytoMed Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CytoMed Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because CytoMed Therapeutics' market value can be influenced by many factors that don't directly affect CytoMed Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CytoMed Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CytoMed Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, CytoMed Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.